BioSpace News Archive

MannKind Corporation announced that it has agreed to in-license iSPERSE™ technology from Pulmatrix for certain indications in exchange for an out-license of MannKind’s Cricket® inhaler to Pulmatrix for inhaled delivery of dihydroergotamine for migraine treatment.

Cancer Check Labs, a leader in early cancer detection through blood screening tests, along with clinical partners Comprehensive Blood & Cancer Center, the largest private cancer center on the West Coast, and Christus St. Michael, W. Temple Webber Cancer Center, announced results from a breakthrough study demonstrating the ability to detect, capture, and image whole, intact circulating tumor cells from Stage 0 and Stage 1 breast cancer patients.

MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) (“MIRA” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the treatment of neurologic and neuropsychiatric disorders, announced that MIRA-55, has been determined by the U.S. Drug Enforcement Administration (DEA) not to be a controlled substance or listed chemical under the Controlled Substance Act and its governing regulations.

Remedy Pharmaceuticals announced that prespecified subgroup analyses from the Phase 3 CHARM clinical trial of CIRARA (IV glibenclamide) showed meaningful improvements in functional outcomes on the modified Rankin Scale (mRS), which were further validated in post hoc analyses.

LIB Therapeutics Announces Positive Lerodalcibep Results from Two Phase 3 LIBerate Studies at the 92nd European Atherosclerosis Society Congress.

A2 Biotherapeutics, Inc. will present updates on three ongoing clinical trials in poster presentations during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.

Petros Pharmaceuticals, Inc. announces the successful completion of a Formative Human Factors study of its AI-integrated Web App, designed to facilitate OTC access of STENDRA® (avanafil) for consumers.

In the ever evolving landscape of clinical therapeutics, multispecific antibodies have emerged as a promising class of biologics with the potential to revolutionize treatment strategies for a multitude of diseases.

Houston, Texas--(Newsfile Corp. - May 29, 2024) - Cannabis Bioscience International Holdings (OTC Pink: CBIH) announces the engagement of StoneBridge Advisory (stonebridgema.com) for CBIH’s company valuation.

Cincinnati Children’s has begun work on an Applied Gene and Cell Therapy Center, which will enable the health system to increase clinical trials of innovative drugs and biological therapeutics for patients with cancer, blood diseases or genetic disorders.